Impact of fibrinogen-to-albumin ratio on the long-term prognosis of patients with advanced HER2-negative gastric cancer receiving immunochemotherapy

Table 1 Baseline characteristics of fibrinogen to albumin ratio < 0.08 and fibrinogen to albumin ratio ≥ 0.08, n (%)

Variables	Overall, mean ± SD/n (%), n = 260	Low FAR, mean ± SD/n (%), n = 123	High FAR, mean ± SD/n (%), n = 137	P value
Fibrinogen, g/L	3.63 ± 0.91	2.91 ± 0.55	4.27 ± 0.66	< 0.001
Albumin, g/L	40.24 ± 4.86	42.30 ± 4.48	38.40 ± 4.43	< 0.001
FAR	0.09 ± 0.03	0.07 ± 0.01	0.11 ± 0.02	< 0.001
Sex				0.799
Female	129 (49.62)	60 (48.78)	69 (50.36)
Male	131 (50.38)	63 (51.22)	68 (49.64)
Age, years				0.861
< 60	119 (45.77)	57 (46.34)	62 (45.26)
≥ 60	141 (54.23)	66 (53.66)	75 (54.74)
Drinking history				0.264
No	180 (69.23)	81 (65.85)	99 (72.26)
Yes	80 (30.77)	42 (34.15)	38 (27.74)
Smoking history				0.932
No	179 (68.85)	85 (69.11)	94 (68.61)
Yes	81 (31.15)	38 (30.89)	43 (31.39)
Body mass index, kg/m2				0.286
< 25	200 (76.92)	91 (73.98)	109 (79.56)
≥ 25	60 (23.08)	32 (26.02)	28 (20.44)
ECOG				0.669
0	172 (66.15)	83 (67.48)	89 (64.96)
1	88 (33.85)	40 (32.52)	48 (35.04)
Site
Stomach	128 (49.23)	68 (55.28)	60 (43.80)	0.062
Gastric and esophageal binding	132 (50.77)	55 (44.72)	77 (56.20)
Histological				0.306
Adenocarcinoma	191 (73.46)	94 (76.42)	97 (70.80)
Others	69 (26.54)	29 (23.58)	40 (29.20)
Staging				0.098
3	80 (30.77)	44 (35.77)	36 (26.28)
4	180 (69.23)	79 (64.23)	101 (73.72)
CEA, ng/mL				0.683
< 3	107 (41.15)	49 (39.84)	58 (42.34)
≥ 3	153 (58.85)	74 (60.16)	79 (57.66)
Peritoneal metastasis				0.172
No	213 (81.92)	105 (85.37)	108 (78.83)
Yes	47 (18.08)	18 (14.63)	29 (21.17)
Liver metastasis				0.815
No	171 (65.77)	80 (65.04)	91 (66.42)
Yes	89 (34.23)	43 (34.96)	46 (33.58)
EBV status				0.826
No-infect	217 (83.46)	102 (82.93)	115 (83.94)
Infect	43 (16.54)	21 (17.07)	22 (16.06)
PD-L1 expression				0.619
CPS < 5	52 (20.00)	23 (18.70)	29 (21.17)
CPS ≥ 5	208 (80.00)	100 (81.30)	108 (78.83)
MMR status				0.113
pMMR	248 (95.38)	120 (97.50)	128 (93.43)
dMMR	12 (4.62)	3 (2.44)	9 (6.57)

FAR: Fibrinogen-to-albumin ratio; ECOG: Eastern Cooperative Oncology Group; CEA: Carcinoembryonic-antigen; EBV: Epstein-Barr virus; PD-L1: Programmed cell death ligand 1; CPS: Combined positive score; MMR: Mismatch repair; pMMR: Proficient mismatch repair; dMMR: Deficient mismatch repair.